Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/17/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
54.59(c) 54.78(c) 55.35(c) 55.77(c) 56.44(c) Last
9 706 078 26 919 342 21 293 710 14 410 368 11 336 921 Volume
+0.57% +0.35% +1.04% +0.76% +1.20% Change
More quotes
Financials ($)
Sales 2017 19 720 M
EBIT 2017 5 198 M
Net income 2017 4 660 M
Finance 2017 422 M
Yield 2017 2,88%
Sales 2018 20 374 M
EBIT 2018 5 535 M
Net income 2018 5 180 M
Finance 2018 1 671 M
Yield 2018 2,92%
P/E ratio 2017 20,41
P/E ratio 2018 18,73
EV / Sales2017 4,77x
EV / Sales2018 4,55x
Capitalization 94 408 M
More Financials
Company
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products.Its pharmaceutical products include chemically-synthesized drugs or small molecules and an increasing portion of products produced from... 
Sector
Pharmaceuticals
Calendar
04/27Earnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Co
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB CO
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Reveals New Findings o..
02/24 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Report Recent Findi..
02/24 BRISTOL MYERS SQUIBB : Trademark Application for "APOTHECON" Filed by Bristol-My..
02/24 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Update Understanding o..
02/23 BRISTOL MYERS SQUIBB : Prices $1.5 Billion of Senior Notes
02/22 Newmont and Papa John's dip; Bristol-Myers and Garmin rise
02/22DJBRISTOL MYERS SQUIBB : New Pressure on Drug Giant -- WSJ
02/22DJWHAT'S NEWS : Business & Finance -- WSJ
02/22 BRISTOL MYERS SQUIBB : Icahn Takes Stake In Bristol-Myers
02/22DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Upd..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on BRISTOL-MYERS SQUIBB CO 
2016Attractive price levels
More Strategies
Latest Tweets
08:07aCarl Icahn can't make Bristol-Myers buyable  
02/24• FRIDAY'S ACTIVE FLOW: $BAC $AAPL $NVDA $TSLA $AMZN $X $C $BMY $MSFT $FCX $A..
7
02/24Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink  
02/24Ties to Gilead, AbbVie and BMS raise questions about hep C drug value studies.. 
02/24Biotech Forum Daily Digest: Trevena Oversold? Bristol-Myers Squibb On The Blo.. 
More tweets
Qtime:146
News from SeekingAlpha
02/24 BIOTECH FORUM DAILY DIGEST : Trevena Oversold? Bristol-Myers Squibb On The Block..
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 FDA OKs Intellipharmaceutics' generic metformin; shares ahead 40% premarket
02/23 Is Pfizer's Research Pipeline Truly Undervalued?
02/22 ALLERGAN'S SAUNDERS : No interest in Valeant
Advertisement
Chart BRISTOL-MYERS SQUIBB CO
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 55,4 $
Spread / Average Target -1,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB C..-4.57%94 408
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
More Results